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 Psoriasis is considered as a genetic, immunological, 
systemic disorder  [1, 2] . With a prevalence of 1–3% and 
estimated annual costs between 650 and 800 USD per 
patient, its socioeconomic impact is remarkable  [3] . Re-
cently developed and upcoming biological treatments of-
fer new therapeutic approaches, but also bring up the old, 
yet still unanswered question: What determines severity 
in psoriasis? 
 Only severe diseases justify the application of agents 
with signiﬁ cant adverse drug reaction (ADR) proﬁ les. 
Systemic treatments are frequently approved exclusively 
for severe or moderate to severe psoriasis. The lack of a 
unanimous deﬁ nition of severity in psoriasis might be 
one of the reasons for the restrictive use of systemic treat-
ment modalities in psoriasis. 
 Generally, there is a consensus that clinical manifesta-
tions like psoriatic arthritis, psoriasis pustulosa, psoriatic 
erythroderma as well as some cases of psoriasis palmo-
plantaris and inverse psoriasis per se are to be considered 
as severe. 
 However, there is much confusion about the deﬁ nition 
of severity in chronic plaque-type psoriasis, which by far 
is the most common clinical manifestation of psoriasis. 
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 Abstract 
 Background:  Chronic plaque-type psoriasis is a major 
dermatosis, but a signifi cant question is still unanswered: 
What defi nes severity in chronic plaque-type psoriasis? 
While objective assessments like the Psoriasis Area and 
Severity Index (PASI) have frequently been used in clin-
ical trials, quality of life (QOL) questionnaires are cur-
rently becoming more and more popular.  Objective:  This 
article summarizes the most important objective and 
subjective measurements of severity in psoriasis. For ev-
ery dermatologist it is critically important to distinguish 
between severe psoriasis and psoriasis that severely af-
fects QOL. Even if the PASI also has disadvantages, it is 
the most adequate instrument available to evaluate se-
verity in plaque-type psoriasis.  Result:  We provide rea-
sons why PASI  1 12 defi nes severe, PASI 7–12 moderate 
and PASI  ! 7 mild chronic plaque-type psoriasis. 
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 Severity Assessments in Plaque-Type 
Psoriasis 
 The characteristic red, scaly, indurated lesion of 
plaque-type psoriasis varies over time in intensity, extent, 
distribution and associated symptoms, e.g. pruritus. In 
some patients, psoriasis severely affects everyday life and 
self-conﬁ dence, and leads to social stigmatization  [4] . The 
response to and amount of previous remedies, as well as 
the time needed for daily treatment are additional factors 
inﬂ uencing disease severity. Unfortunately, laboratory 
tests that accurately measure severity in psoriasis do not 
exist. 
 In order to deﬁ ne inclusion criteria in clinical trials, 
several so-called objective assessments have been devel-
oped to measure the severity of psoriasis. Concerns about 
the clinical relevance of an improved objective score led 
to the introduction of instruments to measure the pa-
tient’s well being/quality of life (QOL). Additionally, 
scores combining objective and subjective subscales have 
been introduced to evaluate the different aspects of dis-
ease severity in a single assessment. 
 Disease-associated discomfort, disability and im-
paired QOL are continuous variables. However, in as-
sessments that focus on whether clinical action should be 
taken, it is more practical to translate this continuum into 
dichotomous or polychotomous variables and thereby as-
sume a threshold. 
 As in diagnostic screening tests, validity and reliabil-
ity are important concerns in clinical measures. Evaluat-
ing the validity of a clinical score might be difﬁ cult, as no 
‘gold standard’ exists. As a surrogate, the validity can be 
determined by the independent judgment of experienced 
clinicians. The intra- and interobserver reliability of clin-
ical assessments should also be formally tested before 
their broader application. 
 In the following, the most common instruments to 
measure disease severity in psoriasis are shortly summa-
rized. Because of the plethora of different instruments it 
is not possible to mention them all. 
 Body Surface Area 
 Several objective assessments incorporate an estima-
tion of the involved body surface area (BSA)  [5] . The BSA 
is easily evaluated either by the ‘rule of nines’ method or 
by the number of patient’s hand areas affected. For de-
cades, the area of one side of a ﬂ at closed patient’s hand 
has been counted for 1% of his total BSA  [6] . However, 
planimetric investigations suggested that one hand actu-
ally represents 0.70–0.76% of the BSA  [7] . This might be 
one reason why the affected BSA is often overesti-
mated. 
 High interobserver variability is an important concern 
 [8] . As a single instrument, BSA is not adequate to deﬁ ne 
the severity of plaque-type psoriasis, as it does not con-
sider the intensity of the psoriatic lesion. 
 Psoriasis Area and Severity Index 
 The Psoriasis Area and Severity Index (PASI) was de-
veloped by Fredriksson and Pettersson  [9]  in 1978 to as-
sess the effect of retinoid treatment in chronic plaque-
type psoriasis. For other clinical manifestations of pso-
riasis, the PASI is not adequate. Both intensity and extent 
(BSA) of the psoriatic plaques are calculated separately 
for four anatomical regions (head, trunk, upper and low-
er extremities) by the physician. The intensity of erythe-
ma, desquamation and induration is rated on a 5-point 
scale with 0 indicating no involvement, 1 slight, 2 moder-
ate, 3 severe and 4 very severe characteristics. The per-
centage of involvement of the four anatomical regions is 
assigned a numerical value of 0–6 with 0 indicating no 
involvement, 1 = 1–9%, 2 = 10–29%, 3 = 30–49%, 4 = 
50–69%, 5 = 70–89% and 6 = 90–100% BSA involve-
ment. When calculating the PASI, the four anatomical 
regions are evaluated according to their proportion of the 
whole integument. The PASI score varies from 0 to 72. 
Higher scores indicate severer conditions.  Table 1 sum-
marizes well-known advantages and disadvantages of the 
PASI. 
 Self-Administered PASI 
 The Self-Administered PASI (SAPASI) was designed 
in order to let the patient calculate the objective severity 
of his current psoriatic plaques  [10] . It consists of a sil-
houette of the body to shade in the affected areas and of 
three visual analogue scales to rate the erythema, indura-
tion and scaliness of one’s own average lesion. A third 
person transforms the patient’s ratings into the intensity 
and extent scales of the PASI. The SAPASI is well vali-
dated and has a high test-retest reliability (r = 0.82)  [5] . 
As an objective score, it is suitable for epidemiological 
studies, when the assessment cannot be performed by a 




 Dermatology 2005;210:194–199 196
 Physician’s Global Assessment/Physician’s 
Static Global Assessment 
 Compared to the mentioned assessments the Physi-
cian’s Global Assessment (PGA)/Physician’s Static Glob-
al Assessment provides a more subjective evaluation of 
overall disease severity. Unfortunately, the term PGA is 
used for two different instruments  [12, 13] : in clinical tri-
als, the PGA is frequently used to evaluate improvement 
relative to baseline severity  [11] . Recently, the Food and 
Drug Administration has criticized that correct PGA as-
sessment depends on the investigator’s exact memory of 
baseline severity  [14] . The other version of the PGA – 
sometimes also called Physician’s Static Global Assess-
ment – evaluates the overall severity without respect of 
baseline characteristics. 5-, 6-, 7- or 8-point scales are 
used, and there is no consensus about scale deﬁ nition. For 
example, a score of ‘3’ can either mean ‘mild’ or ‘moder-
ate’ disease  [11, 13] . 
 Dermatology Life Quality Index 
 The Dermatology Life Quality Index (DLQI) is a wide-
ly used, simple and practical dermatology-speciﬁ c QOL 
instrument. Patients answer 10 questions considering 
their QOL during the previous week on a 4-point scale, 
indicating ‘not at all’, ‘a little’, ‘a lot’ and ‘very much’, 
respectively  [15] . The total DLQI score represents the 
sum of the scores for each question and ranges from 0 to 
30 with higher scores reﬂ ecting worse QOL. Internal con-
sistency and construct validity are strong  [11] . Thus, the 
DLQI is an adequate instrument to assess the QOL in 
psoriasis patients  [16] . 
 Psoriasis Disability Index 
 The Psoriasis Disability Index (PDI) is a validated 
self-administered psoriasis-speciﬁ c questionnaire origi-
nally consisting of 10 questions about aspects of the pa-
tient’s functional disability during the previous 4 weeks 
 [17] . Versions of the PDI using 15 questions have also 
been used  [18] . The questions reﬂ ect daily activities, 
work, personal relationship and treatment. Answers are 
recorded on a 4-point scale, indicating grades from ‘not 
at all’ to ‘very much’  [19] . The PDI correlates strongly 
with the DLQI but does not correlate better than the 
DLQI with objective scores like the PASI or SAPASI 
 [18] . 
 Psoriasis Life Stress Inventory 
 The Psoriasis Life Stress Inventory has been devel-
oped in order to investigate which speciﬁ c behavioral and 
social factors account for the decreased QOL in psoriasis 
patients  [20] . The 15-item questionnaire evaluates the 
patient’s level of stress experienced over the previous 
month on a 4-point scale, from ‘not at all’ to ‘a great deal’. 
It measures psoriasis-speciﬁ c psychological/psychosocial 
problems, many of which arise from anticipation of oth-
er people’s reactions  [21] . The Psoriasis Life Stress Inven-
tory strongly correlates with the DLQI and the PDI, but 
not with the PASI and SAPASI  [18] . 
 Table 1. Advantages and disadvantages of the PASI 
Advantages of the PASI
‘Gold standard’ in clinical trials [25]
Allows historical comparison with several treatments
Good correlation with other objective outcome measures
[5, 23, 28] 
Most validated objective measurement of psoriasis severity [24]
Good interobserver correlation when measured by trained
observers [22]
Test-retest variability is less than 2% [11]
Easy performance
Disadvantages of the PASI
No correlation with QOL [18]
Does not always accurately predict severity from the patient’s
point of view [24]
Concerns about interrater reliability in BSA calculation [8]
No linear relationship to severity
Redundance of half of the range (scores of 35 or more are rare)
Majority of patients are included in the lowest area category
(1–9% BSA)
Does not translate value ranges into the categories mild,
moderate, severe
Erythema and scaling are inﬂ uenced by temperature, humidity
and recent application of emollients [5]
No reﬂ ection of the course over time
No reﬂ ection of the response to former therapies
No special consideration of particular locations, e.g. hands, 
feet, face, genitals
Certain therapies (e.g. anthralin) induce erythema and initially
cause increased scores [29]
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 Salford Psoriasis Index 
 The Salford Psoriasis Index is a 3-component system 
incorporating the current objective severity based on the 
PASI, a psychosocial compound and the treatment his-
tory. Each subscore is reported separately on an 11-point 
scale (0–10)  [22] . The PASI is transformed into the so-
called extent subscore. A visual analogue scale is used to 
evaluate the psychosocial impact. The treatment history 
subscore is calculated by counting 1 point for each sys-
temic therapy applied shorter and 2 points for each ap-
plied longer than a year. Every 5 admissions for inpatient 
treatment, as well as every episode of erythrodermia 
count 1 point. Additionally, a total cumulative dose of 
PUVA exceeding 200 treatments or 1,000 J cm 2  is worth 
1 point. 
 Extent and psychosocial impact subscores both have a 
high test-retest reliability  [11] . The extent subscore does 
not correlate with the other two components of the Sal-
ford Psoriasis Index, but with the PASI and SAPASI. 
There is a strong correlation between the psychosocial 
subscore and the PDI, PASI and SAPASI  [23] . Although 
the Salford Psoriasis Index was designed to assist the cli-
nician in everyday practice, at least the third component 
seems to be too difﬁ cult to be applied regularly  [11] . 
 Data from Clinical Trials 
 An indirect deﬁ nition for ‘mild’, ‘moderate’ and ‘se-
vere’ chronic plaque psoriasis can be derived from ran-
domized controlled trials (RCTs). When a drug is ap-
proved, data from the corresponding clinical trial be-
come critically relevant: safety and efﬁ cacy have been 
proven evidently only for the included population. The 
investigated drug is approved for the disease proﬁ le 
 studied in the phase III RCT.  Table 2 lists data from 
relevant RCTs concerning the severity deﬁ nition of 
plaque-type psoriasis. As we cannot assume a Gaussian 
distribution of psoriasis severity in the patients treated 
in these trials, it is not possible to derive an exact deﬁ ni-
tion of severity of psoriasis from the dispersion of the 
accordant data. 
 Proposed Defi nition 
 Generally, only patients with severe diseases are can-
didates for remedies with signiﬁ cant ADR proﬁ les. Eth-
ical considerations permit the application of such drugs 
only in patients who will probably beneﬁ t from them. 
 If the objective intensity and extent of a patient’s 
plaque-type psoriasis is mild, but psoriasis has signiﬁ -
cant impact on his QOL and self-conﬁ dence, none of the 
systemic treatment modalities is likely to improve his 
situation signiﬁ cantly. By contrast, the ADR proﬁ le of 
the common systemic antipsoriatic remedies would pro-
hibit their use. For the mentioned patient, teaching of 
 Table 2. Deﬁ nition of severity of chronic plaque-type psoriasis in RCTs 
RCT Inclusion criteria Approved indication
therapy phase PASI/BSA termed severity
Alefacept [13] III BSA 610 chronic plaque-type
psoriasis
moderate to severe chronic 
plaque-type psoriasis





moderate to severe chronic 
plaque-type psoriasis





to date not approved for
plaque-type psoriasis
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coping strategies combined with topical drugs would be 
adequate. 
 Thus, it is extremely important to distinguish be-
tween severe psoriasis and psoriasis that severely affects 
QOL. This differentiation is necessary due to ethical 
considerations and shall not lead to an underestimation 
of the patient’s point of view. Severe plaque-type pso-
riasis is characterized by the intensity and extent of pso-
riatic plaques. Although there are several disadvantages 
( table 1 ), the PASI is the best and most common instru-
ment available to measure the mentioned characteristics 
 [24, 25] . Thus, we propose to deﬁ ne severity of chronic 
plaque-type psoriasis by means of the PASI. 
 In doing so, deﬁ ned PASI ranges have to be translat-
ed into the terms ‘mild’, ‘moderate’ and ‘severe’. 
 • A psoriatic plaque is clinically signiﬁ cant if either er-
ythema, induration or scaling is at least ‘severe’, and 
the other two characteristics are at least ‘moderate’. 
In terms of the PASI, the minimum total plaque in-
tensity of such a lesion is 7  [24] . 
 • Patients with a PASI  1 12 have either 10–29% of their 
skin covered with clinically signiﬁ cant plaques or a 
BSA involvement of at least 30% without respect of 
the plaque intensity. Patients meeting these criteria 
deﬁ nitely have severe psoriasis. 
 • A patient with a single deep red, very thick and scaly 
plaque on the back, the extremities and the scalp has 
a PASI = 12, unless BSA involvement is only 1%. This 
patient does not meet the criteria of severe psoriasis. 
Thus, we propose PASI = 12 as the upper limit of 
moderate plaque-type psoriasis. 
 • Clinically signiﬁ cant plaques covering less than 10% 
of the integument deﬁ ne the lower limit of moderate 
plaque-type psoriasis and result in a PASI = 7. 
 • If a patient’s plaques are not clinically signiﬁ cant and 
BSA involvement is less than 10%, the PASI is less 
than 7 and the severity of plaque-type psoriasis is to 
be considered as mild. 
 We propose to deﬁ ne: 
 PASI  1 12 as severe chronic plaque-type psoriasis;  
 PASI 7–12 as moderate chronic plaque-type psoriasis; 
 PASI  ! 7 as mild chronic plaque-type psoriasis. 
 Discussion 
 The proposed deﬁ nition is useful exclusively for chron-
ic plaque-type psoriasis. Other clinical manifestations 
like psoriatic arthritis, psoriasis pustulosa, psoriatic eryth-
roderma as well as some cases of psoriasis palmoplan-
taris and inverse psoriasis are generally to be considered 
severe. 
 Feldman  [24]  has recently stated that PASI and BSA 
deﬁ ne severity of chronic plaque-type psoriasis in RCTs, 
while the impact on the patient’s QOL deﬁ nes severity in 
clinical practice. He differentiates between ‘severe dis-
ease’  (objective criteria) and ‘really  severe disease’  (sub-
jective criteria). Two deﬁ nitions of severity of one and 
the same disease – one for clinical trials and one for clin-
ical practice – are not rational and necessarily lead to 
questioning the idea of evidence-based medicine. 
 As BSA involvement is not the critical criterion from 
the patient’s point of view, Krueger et al.  [26]  propose a 
more comprehensive, patient-related deﬁ nition of sever-
ity in psoriasis in clinical trials. From the patient’s point 
of view ‘embarrassment over  appearance’ is considered 
as very characteristic of severe psoriasis, whereas a posi-
tive family history is regarded as beneﬁ cial  [27] . These 
factors are certainly not adequate to deﬁ ne disease sever-
ity in the context of indications for drug treatment. 
 Both the European Agency for the Evaluation of Med-
ical Products and the Food and Drug Administration 
consider PASI and BSA as adequate to deﬁ ne severity
in psoriasis (http://www.emea.eu.int/pdfs/human/ewp/
245402en.pdf). A major advantage of the PASI is that it 
enables historical comparison between different clinical 
trials. Since the change of the millennium, the PASI has 
become even more popular: while used in 33.3% of all 
RCTs evaluating psoriasis therapy between 1977 and 
2000, the PASI was adopted by 59.2% of the RCTs be-
tween 2001 and 2003  [25] 1 . Despite the above-mentioned 
disadvantages ( table 1 ), the PASI is the best-evaluated 
objective method that we have to deﬁ ne disease severity 
in plaque-type psoriasis  [24] . In order to reduce the vari-
ability of the PASI, it would be rational to standardize 
the time interval between the application of emollients 
and PASI evaluation. 
 Patients with a PASI greater than 12 deﬁ nitely have 
severe psoriasis and are most likely to beneﬁ t from sys-
temic remedies. The chance to signiﬁ cantly improve the 
severity of their psoriatic lesions justiﬁ es possible ADRs 
of systemic agents like cyclosporine or methotrexate. 
 The major concern about the PASI is that its reduction 
is  not in all patients  translated into an improvement of 
QOL  [4, 18, 24] . On the other hand, QOL correlates with 
 
 1  Naldi L: The EDEN Psoriasis Project (oral presentation). EDEN Sympo-
sium – How to Perform Effective Clinical Trials for Psoriasis, Geneva, April 
2004. 
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psoriasis-related stress. That again mainly derives from 
the patient’s ability to anticipate the reactions of others 
and might be improved by adequate coping strategies 
 [21] . Furthermore, psychological distress often has a det-
rimental effect on treatment outcome. 
 If a patient’s QOL is very much affected, but the PASI 
is low, the success of a conventional therapeutic interven-
tion is unlikely. Thus, it seems to be logical that patients 
with a disproportionate impact on QOL might beneﬁ t 
signiﬁ cantly from coping strategies. With respect to evi-
dence-based medicine, however, this hypothesis should 
be evaluated in a randomized controlled trial. 
